Metabolic syndrome in haemodialysis patients: Prevalence, determinants and association to cardiovascular outcomes
Abstract Background In the general population, the metabolic syndrome (MetS) has been identified as predictive of major adverse cardiovascular events (MACE). Waist circumference (WC), a component of the MetS criteria, is linked to visceral obesity, which in turn is correlated with MACE. However, in haemodialysis (HD) patients, the association between MetS, WC and MACE is unclear.Methods In a cross-sectional study of 1000 HD patients, we evaluated the prevalence and characterised the clinical predictors of MetS. The relationship between MetS and its components, alone or in combination, and MACE, as defined by comorbidity among coronary diseases, peripheral arteriopathy, stroke or cardiac failure, was further studied using receiver operating characteristics (ROC) curves and logistic regression.Results A total of 753 patients were included between October 2011 and April 2013. The prevalence of MetS was 68.5%. Waist circumference (> 88 cm in women, 102 cm in men) was the best predictor of MetS (sensitivity 80.2; specificity 82.3; AUC 0.80; p < 0.05). In multivariate analysis, MetS was associated with MACE (OR: 1.85; 95CI 1.24-2.75; p < 0.01), but not WC alone. There was a stronger association between the combination of abdominal obesity, hypertriglyceridaemia and low high-density lipoprotein cholesterol with MACE after exclusion of impaired fasting glucose and hypertension.ConclusionsMetS is frequent and associated with MACE in HD patients in our region and probably in other European dialysis populations. In HD patients, a new simplified definition could be proposed, in keeping with the concept of hypertriglyceridaemic waist.